JB Chemicals Poised For Growth In The Medium-Term - Analyst Meet Takeaways: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
JB Chemicals and Pharmaceuticals Ltd. hosted virtual analyst meet to share its mid to long term vision post the change in management after the buyout by private equity firm KKR (54%) in July 2020.
The new management laid out a six-point framework for sustainable mid-teens growth via therapy diversification, productivity improvement, leveraging existing capabilities in contract manufacturing outsourcing, exploring mergers and acquisitions (brands, portfolio) and focus on deepening existing base through digitization.
The company’s revenue base is equally divided between India (formulations) and exports (formulation, CMO and active pharmaceutical ingredient).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.